Atlanta Journal Constitution: Ointment kills antibiotic-resistant bacteria, promotes wound healing
Drug developed by UC researcher could be effective against 'superbugs'
Research at the University of Cincinnati College of Medicine may have added a weapon to hospitals’ bacteria fighting arsenal.
Using the topical drug called AB569 — a combination of acidified nitrite and ethylenediaminetetraacetic acid — promotes killing of antibiotic-resistant bacteria while enhancing the healing of wounds in a variety of burn injuries, the study found. The study was published in the journal Infection and Immunity.
The Atlanta Journal Constitution published a story on the research by Daniel Hassett, PhD, professor in the Department of Molecular Genetics, Biochemistry and Microbiology at the UC College of Medicine. Hassett patented AB569 in 2018.
Daniel Hassett, PhD, professor in the Department of Molecular Genetics, Biochemistry and Microbiology at the UC College of Medicine/Photo/Colleen Kelley/UC Creative + Brand
His research has found that AB569 kills virtually all pathogenic bacteria tested. Those bacteria are some of the most serious pathogens exhibiting multidrug resistance and enhanced virulence properties, according to the Centers for Disease Control and Prevention.
“Multidrug resistant bacteria, often called ‘superbugs,’ are an ever-burgeoning global health problem,” Hassett said. “As a result, there is a critical need to develop novel and effective antimicrobials for the prevention, treatment and eradication and healing of such wounds that are complicated by the most formidable pathogen of burn patients, known as MDR-PA. Injury severity is predominantly due to potentially lethal sepsis caused by MDR-PA.”
AB569 was first seen as a treatment for antibiotic-resistant organisms that cause pulmonary infections in patients with cystic fibrosis and chronic obstructive pulmonary disease, and many other opportunistic infections. In addition to tackling COPD and cystic fibrosis, AB569 may also be effective in addressing infections related to severe burns, urinary tract disorders, endocarditis and diabetes, Hassett said.
Hassett was also interviewed about this research by WVXU. See that coverage here.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Put down that beer; it's not a tanning lotion
July 1, 2024
The University of Cincinnati's Kelly Dobos joined WVXU's Cincinnati Edition to discuss what's fact and what's myth when it comes to sunscreen use, different kinds of sunscreen and a social media recommendation to use beer on your skin to help get a tan.
Cincinnati researchers want to know if MRIs can work better
June 28, 2024
WVXU and the Cincinnati Business Courier highlighted a new collaboration between the University of Cincinnati College of Medicine, UC Health GE HealthCare, JobsOhio, REDI Cincinnati and Cincinnati Children’s to create an MRI Research and Development Center of Excellence located on UC’s medical campus.
UC opens Blood Cancer Healing Center
June 28, 2024
Media outlets including WLWT, Local 12, Spectrum News, the Cincinnati Enquirer and Cleveland.com highlighted the opening of the University of Cincinnati Cancer Center's Blood Cancer Healing Center.